GlassScriptPhysician profile
Helen E Heslop
NPI 1912087271
$51,344.18
in general payments reported to CMS, 2019-2025
9 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $1,800 · 2021: $6,000 · 2022: $1,714 · 2023: $489 · 2024: $986 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289 · Travel and Lodging: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.98 |
| Travel and Lodging | $427.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $27,814.58 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $14,136.74 | 2019-2023 | |
| Glaxosmithkline, LLC. | $4,875.00 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,500.00 | 2021 | |
| National Marrow Donor Program | $1,732.83 | 2022-2024 | |
| Autolus INC | $146.47 | 2025 | |
| Pfizer INC. | $94.24 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $24.33 | 2023 | |
| Kite Pharma, INC. | $19.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Heslop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.